[Analysis of the chemosensitivity test by human tumor clonogenic assay and subrenal capsule assay].
The antitumor activities of several chemotherapeutic agents were tested in the human tumor clonogenic assay (HTCA) and in subrenal capsule assay (SRCA). The results obtained in these two assays and clinical response were compared. 1. Colony growth was observed in 43 of 73 tumors (58.9%), and the adequate colony growth to evaluate the response of therapeutic groups was obtained in 21 tumors (28.8%). 2. Control growth adequate to meet evaluable assay criteria was obtained in 38 of 43 tumors (88.4%). 3. With activity criteria set at a decrease of greater than or equal to 50% in tumor colony-forming units for the HTCA and a change in tumor size less than or equal to -1.0 dmm for the SRCA, 24 of 98 drugs tested were active in HTCA (24.5%), and 50 of 160 drugs were active in SRCA (31.2%). 4. A total of 21 tumors was tested in both HTCA and SRCA and the tumor response was compared in 12 tumors treated with 39 drugs. Correlation of tumor responses between the two assays was 71.8%. 5. A total of 8 HTCA-clinical correlations and 5 SRCA-clinical correlations were possible. Overall predictive accuracy was 87.5% in the HTCA and 80.0% in the SRCA, respectively.